A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first
In downtown Lowell, MA, tucked into one of the country’s oldest surviving textile mill complexes is a new biotech toiling away on next-gen CNS therapies for severe neurological disorders. And it’s starting with Rett syndrome — a rare neurodevelopmental condition that almost exclusively affects girls.
Alcyone Therapeutics emerged from stealth mode Wednesday with $23 million from RTW Investments and 12 new gene therapy programs in the works. The company was created last summer, shortly after founder and CEO PJ Anand met Kathrin Meyer, a principal investigator in the gene therapy unit at the Abigail Wexner Research Institute at Nationwide Children’s Hospital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
